Breaking News, Trials & Filings

Trials & Filings in Brief: Dec. 11, 2013

AbbVie, Avanir, Baxter, Genzyme, KaloBios, Merck, Orexigen, QRxPharma, Seattle Genetics

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase I KaloBios succeeds in early-stage trial . . . read more Phase II Seattle Genetics updates Adcetris DLBCL data . . . read more Phase III AbbVie regimen wallops HCV . . . read more Avanir pain drug misses endpoint in MS pain trial . . . read more Merck advances Alzheimer’s drug . . . read more Filings Baxter submits OBI-1 BLA . . . read more Genzyme Gaucher treatment gets priority review . . . read more Orexigen resubmits Contrave NDA . . . read more QRxPharma MOXDUO PDUFA dat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters